Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up

Main Article Content

Danny Rischin
Nikhil Khushalani
Chryslalyne Schmults
Alexander Guminski
Anne Lynn Chang
Karl Lewis
Annette Lim
Leonel Hernandez-Aya
Brett Hughes
Dirk Schadendorf
Axel Hauschild
Elizabeth Stankevich
Jocelyn Booth
Suk-Young Yoo
Zhen Chen
Emmanuel Okoye
Israel Lowy
Matthew Fury
Micahel Migden

Keywords

Skin Cancer, Squamous Cell Carcinoma, Biologic, PD-1 Inhibitor, Cemiplimab

Abstract

Abstract not available.

References

1. Que SKT et al. J Am Acad Dermatol. 2018;78:237–247.

2. Cranmer LD et al. Oncologist. 2010;15:1320–1328.

3. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: squamous cell skin cancer (Version 2.2019). 2018. Available at: https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf. [Accessed March 20, 2020].

4. Karia PS et al. J Clin Oncol. 2014;32:327–334.

5. Weinberg AS et al. Dermatol Surg. 2007;33:885–899.

6. Schmults CD et al. JAMA Dermatol. 2013;149:541–547.

7. Cowey C et al. Cancer Med. 2020 [in press].

8. Burova E et al. Mol Cancer Ther. 2017;16:861–870.

9. Migden MR et al. Lancet Oncol. 2020;21:294–305.

10. Migden MR et al. N Engl J Med. 2018;379:341–351.

11. Rischin D et al. Poster presented at Maui Dermatology Conference, January 25–29, 2020.

12. Eisenhauer EA et al. Eur J Cancer. 2009;45:228–247.